Evaluation of Bronchial Constriction in Children With Cystic Fibrosis After Inhaling Two Different Preparations of Tobramycin

摘要: Objectives This randomized, double-blind, cross-over study evaluated the risk of bronchoconstriction with two preparations inhaled tobramycin in children cystic fibrosis (CF) infected Pseudomonas aeruginosa and without airway hyperreactivity. Design Of 19 CF (age range, 7 to 16 years) mild-to-moderate pulmonary disease, 10 were at high (HR) for bronchospasm (family history asthma previous response bronchodilators) 9 low (LR) (no family or bronchodilators). Two solutions administered: (1) 80 mg a 2-mL vial diluted 2 mL saline solution containing preservatives phenol bisulfites (IV preparation); (2) 300 preservative-free preparation 5-mL solution. Following bronchodilator-free period 12 h, patients either one other random order on different occasions, weeks apart. Results Prechallenge postchallenge results LR group showed percentage fall FEV 1 (ΔFEV ) ± 9% (mean SD) IV preparation, compared 4 5% (p = 0.046). An ΔFEV > 10% was seen six nine preparation. For HR group, 17 13% IV-preparation 12% 0.4). In this equal numbers (8 patients) had an after inhaling each The largest 44% (HR that forced early termination inhalation). Conclusions Both caused significant preservative-containing more than Heightened reactivity places them from inhalation therapy.